Total Payments
$929,379
2024 Payments
$114,692
Companies
26
Transactions
525
Medicare Patients
237
Medicare Billing
$34,391
Payment Breakdown by Category
Consulting$699,362 (75.3%)
Travel$114,795 (12.4%)
Other$71,178 (7.7%)
Research$31,314 (3.4%)
Food & Beverage$12,731 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $699,362 | 220 | 75.3% |
| Travel and Lodging | $114,795 | 130 | 12.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $59,234 | 14 | 6.4% |
| Unspecified | $31,314 | 3 | 3.4% |
| Food and Beverage | $12,731 | 157 | 1.4% |
| Honoraria | $11,944 | 1 | 1.3% |
Payments by Type
General
$898,066
522 transactions
Research
$31,314
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $196,932 | 3 | $0 (2023) |
| Merck Sharp & Dohme LLC | $183,524 | 178 | $0 (2024) |
| Amgen Inc. | $107,237 | 79 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $84,274 | 48 | $0 (2023) |
| Novo Nordisk AS | $77,263 | 23 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $65,726 | 25 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $35,631 | 37 | $0 (2024) |
| AstraZeneca UK Limited | $33,717 | 26 | $0 (2024) |
| Janssen Research & Development, LLC | $32,479 | 25 | $0 (2023) |
| Aralez Pharmaceuticals US Inc. | $17,557 | 8 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $114,692 | 108 | Amgen Inc. ($31,868) |
| 2023 | $73,776 | 75 | Merck Sharp & Dohme LLC ($24,137) |
| 2022 | $88,284 | 73 | Merck Sharp & Dohme LLC ($38,264) |
| 2021 | $66,970 | 39 | Janssen Research & Development, LLC ($18,291) |
| 2020 | $55,111 | 29 | Janssen Pharmaceuticals, Inc ($16,072) |
| 2019 | $93,430 | 71 | Novo Nordisk AS ($25,870) |
| 2018 | $323,580 | 74 | PFIZER INC. ($196,903) |
| 2017 | $113,537 | 56 | Merck Sharp & Dohme Corporation ($57,401) |
All Payment Transactions
525 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Janssen Global Services, LLC | — | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| 12/17/2024 | Amgen Inc. | Repatha (Biological) | Consulting Fee | Cash or cash equivalent | $687.50 | General |
| Category: Cardiology | ||||||
| 12/17/2024 | Amgen Inc. | Repatha (Biological) | Travel and Lodging | Cash or cash equivalent | $18.99 | General |
| Category: Cardiology | ||||||
| 12/16/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $203.38 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/16/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $203.31 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/16/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $203.31 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/13/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Consulting Fee | Cash or cash equivalent | $3,850.00 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/09/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $414.80 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/09/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $402.60 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/09/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $402.60 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/03/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $4,550.00 | General |
| 12/02/2024 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 11/26/2024 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $106.70 | General |
| 11/26/2024 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $62.85 | General |
| 11/26/2024 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $48.75 | General |
| 11/22/2024 | Novo Nordisk Inc | Victoza (Drug) | Consulting Fee | Cash or cash equivalent | $2,712.50 | General |
| Category: Diabetes | ||||||
| 11/20/2024 | Novo Nordisk AS | — | Consulting Fee | Cash or cash equivalent | $12,981.25 | General |
| 11/20/2024 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $6,819.70 | General |
| 11/20/2024 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $364.18 | General |
| 11/20/2024 | Novo Nordisk AS | — | Food and Beverage | In-kind items and services | $288.23 | General |
| 11/20/2024 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $223.75 | General |
| 11/17/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $48.00 | General |
| Category: Cardiology | ||||||
| 11/16/2024 | AstraZeneca AB | — | Food and Beverage | In-kind items and services | $134.99 | General |
| 11/16/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Cardiology | ||||||
| 11/15/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $149.98 | General |
| Category: CARDIOVASCULAR | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| This First Amendment the Amendment 1 to the Executive Committee Member Agreement dated October 1 2015 the Agreement between Marc Peter Bonaca M D M P H Consultant and The Colorado Prevention Center dba CPC Clinical Research CPC is made effective as of January 12 2016 hereinafter the Amendment 1 Effective Date | Bayer HealthCare Pharmaceuticals Inc. | $31,000 | 1 |
| Perspectives on New Guidelines for Treating Dyslipidemia and Managing Cardiovascular Risk | Amgen Inc. | $300.55 | 1 |
| V1P Study | Novartis Pharma AG | $12.98 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 72 | 106 | $55,382 | $10,529 |
| 2022 | 2 | 40 | 45 | $27,396 | $5,169 |
| 2021 | 4 | 92 | 134 | $66,568 | $13,072 |
| 2020 | 2 | 33 | 48 | $26,796 | $5,621 |
Total Patients
237
Total Services
333
Medicare Billing
$34,391
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 20 | 52 | $21,424 | $4,717 | 22.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 30 | 30 | $24,060 | $3,887 | 16.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 11 | 11 | $4,854 | $999.46 | 20.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 11 | 13 | $5,044 | $925.32 | 18.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 24 | 24 | $19,248 | $3,683 | 19.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 16 | 21 | $8,148 | $1,486 | 18.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 38 | 38 | $30,476 | $5,910 | 19.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 23 | 57 | $23,484 | $4,722 | 20.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 13 | 21 | $7,388 | $1,451 | 19.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 18 | 18 | $5,220 | $988.55 | 18.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 18 | 18 | $14,436 | $3,025 | 21.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 15 | 30 | $12,360 | $2,597 | 21.0% |
About Dr. Marc Bonaca, M.D
Dr. Marc Bonaca, M.D is a Cardiovascular Disease healthcare provider based in Aurora, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1598834590.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Marc Bonaca, M.D has received a total of $929,379 in payments from pharmaceutical and medical device companies, with $114,692 received in 2024. These payments were reported across 525 transactions from 26 companies. The most common payment nature is "Consulting Fee" ($699,362).
As a Medicare-enrolled provider, Bonaca has provided services to 237 Medicare beneficiaries, totaling 333 services with total Medicare billing of $34,391. Data is available for 4 years (2020–2023), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Cardiovascular Disease
- Location Aurora, CO
- Active Since 11/06/2006
- Last Updated 01/14/2019
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1598834590
Products in Payments
- BAVENCIO (Drug) $196,903
- XARELTO (Drug) $126,656
- Repatha (Biological) $98,600
- Xarelto (Drug) $38,063
- Victoza (Drug) $27,083
- BRILINTA (Drug) $23,696
- PRALUENT ALIROCUMAB INJECTION (Biological) $20,245
- ZONTIVITY (Drug) $17,557
- LIPTRUZET (Drug) $15,224
- LEQVIO (Drug) $6,339
- VERQUVO (Drug) $5,596
- EPANOVA (Drug) $3,117
- JARDIANCE (Drug) $2,819
- OPDIVO (Biological) $2,755
- PRALUENT (Biological) $2,119
- IN.PACT Admiral (Device) $2,028
- Neulasta (Biological) $1,650
- LOKELMA (Drug) $600.00
- NEXLETOL (Drug) $362.95
- JANUVIA (Drug) $275.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Aurora
Dr. Gareth Morgan, M.d, M.D
Cardiovascular Disease — Payments: $490,082
Cardiovascular Disease $490,082
Christopher Porterfield, Md Facc, MD FACC
Cardiovascular Disease — Payments: $252,156
Cardiovascular Disease $252,156
Jamaluddin Moloo, Md, MD
Cardiovascular Disease — Payments: $183,878
Cardiovascular Disease $183,878
Dr. Gregory Schwartz, Md Phd, MD PHD
Cardiovascular Disease — Payments: $116,337
Cardiovascular Disease $116,337
Edward Gill, Md, MD
Cardiovascular Disease — Payments: $109,839
Cardiovascular Disease $109,839
Dr. Rhonda Miyasaka, M.d, M.D
Cardiovascular Disease — Payments: $97,294
Cardiovascular Disease $97,294